| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| Targets |
This compound does not possess a specific biological target; its primary function is as a chemical building block for organic synthesis and peptide chemistry. As a glutamic acid derivative, it is used to introduce glutamic acid residues into peptides and other molecules. The phthaloyl group serves as a protecting group for the amino functionality, allowing for selective deprotection under hydrazinolysis conditions. Amino acid and amino acid derivatives have been commercially used as ergogenic supplements. The compound is also known as 2-phthalimidoglutaric acid.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
This compound is not a biological agent and does not exhibit direct in vitro biological activity in a pharmacological sense. Its value lies exclusively in its chemical utility as a protected glutamic acid building block for constructing glutamic acid-containing peptides and other molecules. Amino acids and amino acid derivatives have been commercially used as ergogenic supplements. Any biological activity would reside in the final deprotected product synthesized using this building block, not in the protected intermediate itself. |
| ln Vivo |
2-(1,3-Dioxoisoindolin-2-yl)pentanedioic acid is not administered in vivo as a therapeutic agent. It is a research chemical utilized exclusively as a building block in organic synthesis and peptide chemistry. The final deprotected product, not this protected intermediate, would be the subject of in vivo pharmacological testing for therapeutic efficacy and safety. The phthaloyl-protected amino acid building block itself is never administered to animals as a test compound.
|
| Enzyme Assay |
Non-cellular enzyme/receptor binding assays are not applicable to 2-(1,3-Dioxoisoindolin-2-yl)pentanedioic acid as it is not biologically active. Its use is exclusively in organic synthesis and peptide chemistry. A typical protocol involves its use as a building block in peptide synthesis, where the phthaloyl group can be removed under hydrazinolysis conditions to reveal the free amino group for coupling with other amino acids using standard coupling reagents. The two carboxylic acid groups provide sites for further functionalization or peptide coupling.
|
| Cell Assay |
2-(1,3-Dioxoisoindolin-2-yl)pentanedioic acid is not used in cell-based assays as a therapeutic agent. Its applications are in synthetic chemistry and peptide synthesis. It is typically stored as a powder at -20°C for up to 3 years or at 4°C for up to 2 years; in solvent, it can be stored at -80°C for 6 months or at -20°C for 1 month. The compound is a solid with a molecular weight of 277.23 g/mol. Information concerning product stability, particularly in solution, has rarely been reported.
|
| Animal Protocol |
In vivo animal experiments do not involve 2-(1,3-Dioxoisoindolin-2-yl)pentanedioic acid as a test article. It is a chemical intermediate used exclusively in the synthesis of peptide-based or other drug candidates. If a researcher synthesizes a therapeutic compound using this building block, that final deprotected and purified product would be subjected to animal testing for pharmacokinetics, efficacy, and toxicity. The phthaloyl-protected amino acid itself is never administered to animals as a test compound, as the protecting group would interfere with any potential biological activity and could be toxic.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not applicable to 2-(1,3-Dioxoisoindolin-2-yl)pentanedioic acid as it is not a drug. It is a small molecule (MW 277.23 g/mol) with the formula C13H11NO6. Its properties are relevant for chemical handling and storage rather than for systemic exposure or ADME studies. The compound is not designed to be bioavailable, as the phthaloyl protecting group is intended to be removed during synthesis to yield the final active product.
|
| Toxicity/Toxicokinetics |
The toxicity of 2-(1,3-Dioxoisoindolin-2-yl)pentanedioic acid is not extensively documented, as it is a research chemical not intended for human or veterinary use. As with all phthaloyl-protected amino acids, standard laboratory safety precautions should be followed, including handling in a well-ventilated area with appropriate personal protective equipment (gloves, lab coat, safety glasses). The compound should be stored as a powder at -20°C or below and protected from moisture. It is not intended for diagnostic, therapeutic, or other medical applications.
|
| References | |
| Additional Infomation |
2-Phenylimide glutaric acid is a derivative of glutamic acid.
2-(1,3-Dioxoisin-dolin-2-yl)pentanedioic acid (N-Phthaloyl-DL-glutamic acid) is a protected glutamic acid derivative used as a building block in organic synthesis and peptide chemistry. The phthaloyl group provides a robust protecting group for the amino functionality, which can be removed under hydrazinolysis conditions. The compound contains two carboxylic acid groups, providing multiple sites for chemical modification. This compound is not a pharmaceutical and has no clinical trials or approved therapeutic status. |
| Molecular Formula |
C13H11NO6
|
|---|---|
| Molecular Weight |
277.23
|
| Exact Mass |
277.059
|
| CAS # |
6349-98-0
|
| PubChem CID |
92225
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
192 °C
|
| LogP |
0.538
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
20
|
| Complexity |
436
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C2C(=C1)C(=O)N(C2=O)C(CCC(=O)O)C(=O)O
|
| InChi Key |
FEFFSKLJNYRHQN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H11NO6/c15-10(16)6-5-9(13(19)20)14-11(17)7-3-1-2-4-8(7)12(14)18/h1-4,9H,5-6H2,(H,15,16)(H,19,20)
|
| Chemical Name |
2-(1,3-dioxoisoindol-2-yl)pentanedioic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6071 mL | 18.0356 mL | 36.0711 mL | |
| 5 mM | 0.7214 mL | 3.6071 mL | 7.2142 mL | |
| 10 mM | 0.3607 mL | 1.8036 mL | 3.6071 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
